DermTech, Inc. (DMTK) News

DermTech, Inc. (DMTK): $5.57

0.05 (+0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter DMTK News Items

DMTK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DMTK News Highlights

  • DMTK's 30 day story count now stands at 10.
  • Over the past 22 days, the trend for DMTK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about DMTK are LI, SKIN and LAB.

Latest DMTK News From Around the Web

Below are the latest news stories about DERMTECH INC that investors may wish to consider to help them evaluate DMTK as an investment opportunity.

DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LA JOLLA, Calif., January 27, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to four new employees of restricted stock units representing the contingent right to receive up to an aggregate of 44,669 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The restricted stock units were approved by

Yahoo | January 27, 2023

DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

LA JOLLA, Calif., January 23, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies resulted from an independent technology assessment by the second largest laboratory benefits

Yahoo | January 23, 2023

This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run

DermTech markets genomic tests that are used to diagnose melanoma. The company hasn't reported its full-year 2022 revenue yet, but CEO John Dobak warned in November that it's likely to come in below the previous guidance range. On Jan. 5, 2023, DermTech announced positive coverage decisions from Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Louisiana, and Blue Cross Blue Shield of Kansas City.

Yahoo | January 18, 2023

Institutions profited after DermTech, Inc.'s (NASDAQ:DMTK) market cap rose US$79m last week butindividual investors profited the most

Every investor in DermTech, Inc. ( NASDAQ:DMTK ) should be aware of the most powerful shareholder groups. We can see...

Yahoo | January 16, 2023

DermTech adds 39% on TRICARE coverage

  • Molecular diagnostic company DermTech (NASDAQ:DMTK) is on track to record its higher-ever intraday gain on Tuesday after announcing that a foundational assay in its DermTech Melanoma Test has been recommended for TRICARE coverage.
  • Defense Health Agency’s Lab Joint Working Group has made the recommendation to TRICARE, a healthcare program targeted at U.S. service members, retirees, and their families.
  • “This coverage recommendation makes the foundational assay of the DMT available to TRICARE’s approximately 9 million members and beneficiaries of the Military Health System,” the com...

    Seeking Alpha | January 10, 2023

DermTech Inc. (NASDAQ:DMTK): It’s all about numbers this morning

DermTech Inc. (DMTK)’s stock is trading at $2.71 at the moment marking a rise of 24.29% from the last session close. As of this writing, shares are priced at -83.41% less than their 52-week high of $16.33, and 74.81% over their 52-week low of $1.55. Based on the past 30-day period, the stock price is […]

US Post News | January 10, 2023

DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE

LA JOLLA, Calif., January 10, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world.

Yahoo | January 10, 2023

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (BCBS NC), Blue Cross Blue Shield of South Carolina (BCBS SC), Blue Cross Blue Shield of Louisiana (BCBS LA) and Blue Cross

Wallstreet:Online | January 5, 2023

DermTech (DMTK) Stock: Differentiated Offering To Melanoma Diagnostics, Hold Rating

DMTK''s assay menu provides a differentiated offering to examining and diagnosing melanoma, an otherwise complex task. Read an analysis of DMTK here.

Seeking Alpha | December 22, 2022

DermTech (NASDAQ:DMTK investor one-year losses grow to 89% as the stock sheds US$8.8m this past week

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...

Yahoo | December 20, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6049 seconds.